Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis
NCT00998829
Last updated date
ABOUT THIS STUDY
This study aims to collect Australian data on the prevalence of undiagnosed psoriatic
arthritis in patients with plaque psoriasis. In addition the study will assess disease
severity and quality of life in Australian patients with psoriasis attending specialist
dermatology clinics.
Study Location
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Psoriatic Arthritis, Psoriasis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Diagnosis of plaque psoriasis
- >= 18 years of age
- Able to complete English-language questionnaires
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Participation in an interventional clinical trial in previous 3 months
- Known rheumatologist-confirmed psoriatic arthritis
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Psoriatic Arthritis, PsoriasisStudy Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis
NCT00998829
- Camperdown, New South Wales
- Darlinghurst, New South Wales
- St Leonards, New South Wales
- Westmead, New South Wales
- Carina Heights, Queensland
- Bedford Park, South Australia
- Box Hill, Victoria
- Fitzroy, Victoria
- Parkville, Victoria
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title | Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis | |||
| Official Title | An Australian Cross-Sectional Epidemiological Study To Evaluate The Prevalence Of Undiagnosed Psoriatic Arthritis In Psoriasis Patients In Dermatology Practice Focusing On Disease Severity, Disease Burden And Quality Of Life | |||
| Brief Summary | This study aims to collect Australian data on the prevalence of undiagnosed psoriatic arthritis in patients with plaque psoriasis. In addition the study will assess disease severity and quality of life in Australian patients with psoriasis attending specialist dermatology clinics. | |||
| Detailed Description | Consecutive psoriasis patients seen at each site will be invited to participate in the study | |||
| Study Type | Observational | |||
| Study Design | Observational Model: Case-Only Time Perspective: Cross-Sectional | |||
| Target Follow-Up Duration | Not Provided | |||
| Biospecimen | Not Provided | |||
| Sampling Method | Probability Sample | |||
| Study Population | Specialist dermatology clinics | |||
| Condition |
| |||
| Intervention | Other: questionnaire
There is no therapeutic intervention in this study. However PASE (Psoriatic Arthritis Screening and Evaluation) and other patient questionnaires will be completed by participants. | |||
| Study Groups/Cohorts | Study population
The group comprises the entire study population Intervention: Other: questionnaire | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status | Completed | |||
| Actual Enrollment | 458 | |||
| Original Estimated Enrollment | 500 | |||
| Actual Study Completion Date | May 2012 | |||
| Actual Primary Completion Date | May 2012 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender |
| |||
| Ages | 18 Years and older (Adult, Older Adult) | |||
| Accepts Healthy Volunteers | No | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | Australia | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number | NCT00998829 | |||
| Other Study ID Numbers | 0881A6-4611 B1801063 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement | Not Provided | |||
| Responsible Party | Pfizer | |||
| Study Sponsor | Pfizer | |||
| Collaborators | Not Provided | |||
| Investigators |
| |||
| PRS Account | Pfizer | |||
| Verification Date | November 2012 | |||